Nuklearmedizin. Nuclear medicine最新文献_第3页

Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy. 一名接受[177Lu]Lu-PSMA-617放射性配体治疗的 mCRPC 患者在[68Ga]Ga-PSMA-11 PET/CT 上意外发现胰腺腺癌。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-06-01 Epub Date: 2024-01-08 DOI: 10.1055/a-2221-3220

Giulia Santo, Gianpaolo Di Santo, Bettina Zelger, Irene Virgolini

引用次数: 0

The Role of FDG- PET/CT in Detecting Bone Marrow Involvement in Childhood Solid Tumors. FDG PET/CT 在检测儿童实体瘤骨髓受累方面的作用。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-06-01 Epub Date: 2024-01-08 DOI: 10.1055/a-2224-9441

Esra Arslantaş, Ali Ayçiçek, Burcu Esen Akkas, Tuba Nur Tahtakesen Güçer, Sultan Okur Acar, Ayse Özkan Karagenc, Sibel Akpınar Tekgündüz, Cengiz Bayram

{"title":"The Role of FDG- PET/CT in Detecting Bone Marrow Involvement in Childhood Solid Tumors.","authors":"Esra Arslantaş, Ali Ayçiçek, Burcu Esen Akkas, Tuba Nur Tahtakesen Güçer, Sultan Okur Acar, Ayse Özkan Karagenc, Sibel Akpınar Tekgündüz, Cengiz Bayram","doi":"10.1055/a-2224-9441","DOIUrl":"10.1055/a-2224-9441","url":null,"abstract":"Purpose: To compare the results of 18F-Fluorodeoxy positron emission tomography/computed tomography (18 F-FDG-PET/CT) and bone marrow biopsy (BMB) procedures in the initial evaluation of bone marrow involvement (BMI) in pediatric solid tumors.Methods: We conducted a retrospective analysis of newly diagnosed pediatric cases with lymphoma, neuroblastoma, Ewing sarcoma, rhabdomyosarcoma. Each case underwent both PET-CT imaging and BMB. Presence of tumor infiltration in BMB specimens and/or positive FDG-PET/CT findings indicate as BMI were regarded as true positive results.Results: Sixty-four patients were included in the study. BMI was detected in 23/64 (36%) patients, FDG-PET/CT imaging and BMB results were concordant in 54/64 patients. In 9/64 patients the finding was FDG-PET/CT (+), BMB (-) indicating a false negative BMB result. In only 1/64 patients FDG- PET/CT (-), BMB (+), indicating a false negative FDG-PET/CT result. In the whole patient group, the sensitivity, specificity, positive predictive value and negative predictive value of PET/CT and BMB in detecting bone marrow involvement were 95.6%, 100%, 100% and 97.6% and 60.8 %, 100%, 100% and 82%, respectively.Conclusion: PET/CT has a high sensitivity and specificity for the assessing marrow involvement in pediatric solid tumors. We believe that PET/CT imaging should be performed as the first step in diagnostic staging, and BMB may not be necessary in every patient, only in patients with suspicious PET/CT results for bone marrow involvement. Additionally, for a more precise determination of bone marrow involvement, it is reasonable to perform BMB from FDG-retaining areas, using PET/CT as a guide tool.","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"207-212"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses. 前列腺癌中 Lutetium-177 PSMA 的全球研究成果：文献计量学和 Altmetric 分析。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-06-01 Epub Date: 2024-01-23 DOI: 10.1055/a-2221-3036

Rakan Al-Rashdan, Haneen Al-Abdallat, Mike Machaba Sathekge, Siroos Mirzaei, Mohammed Shahait, Khaled Al-Khawaldeh, Ahmed Saad Abdlkadir, Szeting Lee, Akram Al-Ibraheem

{"title":"Global Research Output of Lutetium-177 PSMA in Prostate Cancer: Bibliometric and Altmetric Analyses.","authors":"Rakan Al-Rashdan, Haneen Al-Abdallat, Mike Machaba Sathekge, Siroos Mirzaei, Mohammed Shahait, Khaled Al-Khawaldeh, Ahmed Saad Abdlkadir, Szeting Lee, Akram Al-Ibraheem","doi":"10.1055/a-2221-3036","DOIUrl":"10.1055/a-2221-3036","url":null,"abstract":"Aim: The integration of innovative radio-pharmaceutical agents targeting prostate-specific membrane antigen (PSMA) within nuclear medicine has transformed prostate cancer detection and management. This study aims to investigate the present landscape of [177Lu]Lu-PSMA in prostate cancer, elucidating trends, global contributions, scholarly outlets, institutions, and thematic concentrations with an aim to inform forthcoming research endeavors.Methods: We systematically probed the Scopus repository for relevant [177Lu]Lu-PSMA literature. An assessment of bibliometric and altmetric data was carried out. Finally, we assessed the correlation between the altmetric attention scores and the number of citations for the retrieved data.Results: Spanning January 2015 to July 2023, the study encompassed 466 articles concerning [177Lu]Lu-PSMA therapy for prostate cancer. Predominant citation accolades gravitated towards metastatic castration-resistant prostate cancer investigations and assessments of [177Lu]Lu-PSMA therapy's safety and efficacy. Further research encompassed adverse effects linked to [177Lu]Lu-PSMA intervention, including xerostomia, thrombocytopenia, anemia, and fatigue. Germany emerged as the primary academic contributor, with The Journal of Nuclear Medicine dominating publications (n = 55). A moderate significant correlation was detected between the number of citations and altmetric attention scores .Conclusion: The findings highlight the growing interest and advancements in the utilization of [177Lu]Lu-PSMA therapy in prostate cancer and offer a comprehensive global perspective on future research directions.","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"188-198"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139543860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic accuracy of artificial intelligence-enabled vectorcardiography versus myocardial perfusion SPECT in patients with suspected or known coronary heart disease. 人工智能矢量心电图与心肌灌注 SPECT 对疑似或已知冠心病患者的诊断准确性对比。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-06-01 Epub Date: 2024-02-20 DOI: 10.1055/a-2263-2322

Simon Aydar, Hermann Knobl, Wolfgang Burchert, Oliver Lindner

{"title":"Diagnostic accuracy of artificial intelligence-enabled vectorcardiography versus myocardial perfusion SPECT in patients with suspected or known coronary heart disease.","authors":"Simon Aydar, Hermann Knobl, Wolfgang Burchert, Oliver Lindner","doi":"10.1055/a-2263-2322","DOIUrl":"10.1055/a-2263-2322","url":null,"abstract":"Aim: The present study evaluated with myocardial perfusion SPECT (MPS) the diagnostic accuracy of an artificial intelligence-enabled vectorcardiography system (Cardisiography, CSG) for detection of perfusion abnormalities.Methods: We studied 241 patients, 155 with suspected CAD and 86 with known CAD who were referred for MPS. The CSG was performed after the MPS acquisition. The CSG results (1) p-factor (perfusion, 0: normal, 1: mildly, 2: moderately, 3: highly abnormal) and (2) s-factor (structure, categories as p-factor) were compared with the MPS scores. The CSG system was not trained during the study.Results: Considering the p-factor alone, a specificity of >78% and a negative predictive value of mostly >90% for all MPS variables were found. The sensitivities ranged from 17 to 56%, the positive predictive values from 4 to 38%. Combining the p- and the s-factor, significantly higher specificity values of about 90% were reached. The s-factor showed a significant correlation (p=0.006) with the MPS ejection fraction.Conclusions: The CSG system is able to exclude relevant perfusion abnormalities in patients with suspected or known CAD with a specificity and a negative predictive value of about 90% combining the p- and the s-factor. Since it is a learning system there is potential for further improvement before routine use.","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"213-218"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11136534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139914369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Radioiodine Treatment on Quality of Life in Patients with Subclinical Hyperthyroidism: A Prospective Controlled Study. 放射性碘治疗对亚临床甲亢患者生活质量的影响：前瞻性对照研究

Nuklearmedizin. Nuclear medicine Pub Date : 2024-06-01 Epub Date: 2024-01-23 DOI: 10.1055/a-2240-8087

Rolf Larisch, John E M Midgley, Johannes W Dietrich, Rudolf Hoermann

{"title":"Effect of Radioiodine Treatment on Quality of Life in Patients with Subclinical Hyperthyroidism: A Prospective Controlled Study.","authors":"Rolf Larisch, John E M Midgley, Johannes W Dietrich, Rudolf Hoermann","doi":"10.1055/a-2240-8087","DOIUrl":"10.1055/a-2240-8087","url":null,"abstract":"Radioiodine treatment (RIT) has a high success rate in both the treatment of hyperthyroidism and improving the quality of life (QoL) of symptomatic patients. In asymptomatic patients with subclinical hyperthyroidism thyroid related QoL outcomes are less well known.Methods: Study aim was to evaluate thyroid-related QoL in patients with subclinical hyperthyroidism mostly due to toxic nodular goitre undergoing RIT, compared to a control group of euthyroid subjects. Study design was monocentric, prospective, controlled. Fifty control subjects were enrolled and 51 RIT patients. Most subjects were examined at least twice at an interval of 6 months, with visits immediately before and 6 months after treatment in the RIT group. QoL was estimated with the ThyPRO questionnaire, using its composite scale as primary outcome. Treatment effect was the mean adjusted difference (MAD) between groups over time, using repeated? measures mixed? effects models.Results: TSH concentrations were lower in the RIT group prior to treatment and recovered thereafter slightly above the level of the control group. Correspondingly, QoL improved significantly after 6 months from a worse level in the RIT group, compared to controls (MAD -10.3 [95% CI -14.9, -5.7], p<0.001). QoL improvements were strong for general items, but less pronounced for the hyperthyroid domain. Compared to controls, thyroid volume, thyroid functional capacity (SPINA-GT) and deiodinase activity (SPINA-GD) were significantly reduced in the RIT group.Conclusion: Patients with subclinical hyperthyroidism improve both biochemically and in their QoL after RIT, compared to controls. QoL assessment should have a wider role in clinical practice to complement biochemical tests and help with treatment decisions.","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"176-187"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139543858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: 99mTc-MDP Bone Scan and 18F-FDG PET/CT Imaging of Primary Hepatic Osteosarcoma. 更正：原发性肝骨肉瘤的 99mTc-MDP 骨扫描和 18F-FDG PET/CT 成像。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-06-01 Epub Date: 2024-03-04 DOI: 10.1055/a-2275-1035

Yao Liu, Wen Tang, Zhongke Huang

引用次数: 0

Dosimetry in a patient with peritoneal dialysis treated with [177Lu]Lu-PSMA-617. 用[177Lu]Lu-PSMA-617治疗一名腹膜透析患者的剂量测定。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-06-01 Epub Date: 2024-01-08 DOI: 10.1055/a-2224-9536

Kathrin Glass, Andreas Hendrik Hering, Alexander Heinzel

引用次数: 0

Peculiar Pattern of Response Following [225Ac]Ac-PSMA Therapy: A Case Report with 'PSA Pseudoregression' Response Pattern. 225Ac]Ac-PSMA治疗后的奇特反应模式：PSA 伪回归 "反应模式的病例报告。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-05-17 DOI: 10.1055/a-2311-5679

Akram Al-Ibraheem, Feras Istatieh, A. Abdlkadir, Alaa’ Abufara, Baha’ Sharaf, R. Abu-Hijlih, NabeelaQublan Al-Hajaj, S. Salah

引用次数: 0

Computational Decision Support for PE Diagnosis based on Ventilation Perfusion Ratio. 基于通气灌注比的 PE 诊断计算决策支持。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-09 DOI: 10.1055/a-2287-2051

Julia Katharina Vogt, Wolfgang Kurt Vogt, Alexander Heinzel, F. Mottaghy

{"title":"Computational Decision Support for PE Diagnosis based on Ventilation Perfusion Ratio.","authors":"Julia Katharina Vogt, Wolfgang Kurt Vogt, Alexander Heinzel, F. Mottaghy","doi":"10.1055/a-2287-2051","DOIUrl":"https://doi.org/10.1055/a-2287-2051","url":null,"abstract":"AIM\u0000The aim of this study is to investigate whether computer-aided, semi-automated 3D lung lobe quantification can support decision-making on PE diagnosis based on the ventilation-perfusion ratio in clinical practice.\u0000\u0000\u0000METHODS\u0000A study cohort of 100 patients (39 male, 61 female, age 64.8±15.8 years) underwent ventilation/perfusion single photon emission computed tomography (V/Q-SPECT/CT) to exclude acute PE on SPECT/CT OPTIMA NM/CT 640 (GE Healthcare). Two 3D lung lobe quantification software tools (Q. Lung: Xeleris 4.0, GE Healthcare and LLQ: Hermes Hybrid 3D Lung Lobar Quantification, Hermes Medical Solutions) were used to evaluate the numerical lobar ventilation/perfusion ratio (VQR) and lobar volume/perfusion ratio (VPR). A test of linearity and equivalence of the two 3D software tools was performed using Pearson, Spearman, quadratic weighted kappa and the mean squared deviation for VPR/VQR. An algorithm was developed that identified PE candidates using ROC analysis. The agreement between the PE findings of an experienced nuclear medicine expert and the calculated PE candidates was represented by the magnitude of the YOUDEN index (J) and the size of the area under the receiver operating curve (AUC).\u0000\u0000\u0000RESULTS\u0000Both 3D software tools showed good comparability. The YOUDEN index for QLUNG(VPR/VQR)/LLQ(VPR/VQR) was in the range from 0.2 to 0.5. The mean AUC averaged over all lung lobes for QLUNG(VPR) was 0.66, CI95%: ±14.0%, for QLUNG(VQR) 0.66, CI95%: ±13.3%, for LLQ(VPR) 0.64, CI95%: ±14.7% and for LLQ(VQR) 0.65, CI95%: ±13.1%.\u0000\u0000\u0000CONCLUSION\u0000This study reveals that 3D software tools are feasible for numerical PE detection. The clinical decision can be supported by using a numerical algorithm based on ROC analysis.","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140723637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL). FDG-PET/CT是预测和评估非霍奇金淋巴瘤（NHL）嵌合抗原受体（CAR）T细胞疗法反应的有力工具。

Nuklearmedizin. Nuclear medicine Pub Date : 2024-04-09 DOI: 10.1055/a-2283-8417

C. Wielenberg, J. Fostitsch, Christian Volz, Reinhard Marks, K. Michalski, Ralph Wäsch, R. Zeiser, Juri Ruf, P. T. Meyer, Claudius Klein

{"title":"FDG-PET/CT is a powerful tool to predict and evaluate response to chimeric antigen receptor (CAR) T-cell therapy in Non-Hodgkin-Lymphoma (NHL).","authors":"C. Wielenberg, J. Fostitsch, Christian Volz, Reinhard Marks, K. Michalski, Ralph Wäsch, R. Zeiser, Juri Ruf, P. T. Meyer, Claudius Klein","doi":"10.1055/a-2283-8417","DOIUrl":"https://doi.org/10.1055/a-2283-8417","url":null,"abstract":"Chimeric antigen receptor (CAR) T-cell therapy has dramatically shifted the landscape of treatment especially for Non-Hodgkin-Lymphoma (NHL). This study evaluates the role of fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) in NHL treated with CAR T-cell therapy concerning response assessment and prognosis.We evaluated 34 patients with NHL who received a CAR T-cell therapy between August 2019 and July 2022. All patients underwent a pre-therapeutic FDG-PET/CT (PET-0) 6 days prior and a post-therapeutic FDG-PET/CT (PET-1) 34 days after CAR T-cell therapy. Deauville score (DS) was used for evaluation of response to therapy and compared to a minimum follow-up of 5 months.19/34 (55.9%) patients achieved DS ≤ 3 on PET-1, the remaining 15 (44.1%) patients had DS > 3 on PET-1. 14/19 patients with DS ≤ 3 on PET-1 had no relapsed or refractory (r/r)-disease and were still alive at last follow-up. The other 5 patients had r/r-disease and 4 of these died. Except for two patients who had no r/r-disease, all other patients (13/15) with DS > 3 on PET-1 had r/r-disease and 12 of these subsequently died. Patients with DS ≤ 3 on PET-1 had significantly better progression free survival (PFS; HR: 5.7; p < 0.01) and overall survival (OS; HR: 5.0; p < 0.01) compared to patients with DS > 3 on PET-1. In addition, we demonstrated that patients with DS ≤ 4 on PET-0 tended to have longer PFS (HR: 3.6; p = 0.05).Early FDG-PET/CT using the established DS after CAR T-cell therapy is a powerful tool to evaluate response to therapy.","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140723118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0